2017 DEA Policy Safety 
Cannabis Law Report
APRIL 8, 2022
Later that year, Doblin sued the DEA for the first time. The FDA formally decided to open the door to psychedelic research in human participants, and later accepted MAPS’ Phase 1 MDMA safety and tolerance study protocol. submitted his first DEA application to manufacture marijuana for use in medical research.
Cannabis Law Report
MAY 29, 2022
8] Spravato is derived from ketamine and categorized by DEA as a Schedule III controlled substance. To mitigate safety risks, FDA implemented a Risk Evaluation and Mitigation Strategy (REMS) with elements to assure safe use (ETASU) whereby patients self-administer the spray in their healthcare provider’s office under medical supervision.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
FloridaMarijuana.net
JULY 8, 2018
According to the MAPS website they are “working to demonstrate the safety and efficacy of smoked botanical marijuana as a prescription medicine for specific medical uses to the satisfaction of the U.S. The study has received full approval from the FDA, DEA, and Institutional Review Boards (IRBs). Food and Drug Administration.
Cannabis Law Report
JULY 1, 2021
The Project on Psychedelics Law and Regulation at the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School will advance evidence-based psychedelics law and policy. Mason Marks: The project’s goal is to promote safety, innovation, equity, and accessibility in emerging psychedelics industries.
Canna Law Blog
MARCH 4, 2020
And as long as the healthcare provider in charge judges the infusion therapy to be ethical and not violative of safety standards, they may prescribe it accordingly. The FDA doesn’t have any regulations on point for the control and oversight of ketamine clinics when it comes to infusion therapy and the states don’t really either.
Cannabis Law Report
JUNE 15, 2021
. – Today, ahead of the 50th anniversary—on June 17—of when President Richard Nixon declared the “war on drugs,” Representatives Bonnie Watson Coleman (D-NJ) and Cori Bush (D-MO) unveiled the Drug Policy Reform Act (DPRA), alongside the Drug Policy Alliance, which has been a strategic partner on the development of the legislation.
Cannabis Law Report
FEBRUARY 28, 2022
Show More According to the Drug Enforcement Administration (DEA), Schedule I drugs have “no currently accepted medical use in the United States, a lack of accepted safety for use under medical supervision, and a high potential for abuse.” In 2017, the FDA designated MDMA a breakthrough therapy for PTSD. Johnson & Roland R.
Expert insights. Personalized for you.
52 
Let's personalize your content